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Ewing’s sarcoma is a childhood bone tumour with poor prognosis, most commonly associated with a t(11;22)(q24;q12) reciprocal
translocation that fuses the EWS and FLI-1 genes, resulting in the production of an aberrant chimeric transcription factor EWS/FLI-1.
To elucidate the mechanisms by which EWS/FLI-1 mediates transformation in mouse models, we have generated a murine Ews/Fli-1
fusion protein. We demonstrate that this protein transforms fibroblast cells in vitro similar to human EWS/FLI-1 as demonstrated by
serum and anchorage-independent growth, the formation of tumours in nude mice and elevation of the oncogenic marker c-myc.
Furthermore, transformation of these cells was inhibited by a specific repressor, KRAB/FLI-1. The KRAB/FLI-1 repressor also
suppressed the tumorigenic phenotype of a human Ewing’s sarcoma cell line. These findings suggest that the transformed phenotype
of Ewing’s sarcoma cells can be reversed by using the sequence-specific FLI-1-DNA-binding domain to target a gene repressor
domain. The inhibition of EWS/FLI-1 is the first demonstration of the KRAB domain suppressing the action of an ETS factor. This
approach provides potential avenues for the elucidation of the biological mechanisms of EWS/FLI-1 oncogenesis and the
development of novel therapeutic strategies.
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Ewing’s sarcoma (ES) and primitive neuroectodermal tumours
(PNET) belong to the Ewing family of tumours, which is a
subgroup of small-round-cell tumours (Ewing, 1984). The clinical
prognosis of individuals with these tumours is poor because of the
lack of specific therapies and a high incidence of relapse (Kovar
et al, 1990; Ambros et al, 1991). Monitoring the disease is also
difficult because of the absence of specific phenotypic markers.
The majority of ES/PNET have been shown to have a
t(11;22)(q24;q12) chromosomal translocation that fuses the amino
terminus of the EWS gene to the carboxyl terminus of the FLI-1
gene (Delattre et al, 1992).
The fusion of an Ets DNA-binding domain (DBD) to EWS
appears to be an important determinant in the generation of ES/
PNET. While 85% of ES/PNET translocations involve FLI-1,
another 5% involve ERG, a closely related ETS transcription factor
and other rarer translocations in ES have included only closely
related members of the ETS family. While human EWS/FLI-1
fusion is capable of transforming, neither the N-terminal EWS nor
FLI-1 DBD domain transformed NIH3T3 cells (May et al, 1993a;
Lessnick et al, 1995). This suggests that the EWS/FLI-1 fusion
protein does not act by blocking the binding of normal cellular
FLI-1 and is consistent with the role of EWS/FLI-1 as a novel
oncogenic transcription factor. Consistent with this hypothesis, in
ES/PNET tumour cell lines or human EWS/FLI-1-transformed
NIH3T3 cells many genes associated with tumorigenesis have also
been shown to be upregulated including c-myc, stromelysin-1,
Manic Fringe, mE2C and EAT-2 (Bailly et al, 1994; Braun et al,
1995; Thompson et al, 1996; May et al, 1997; Arvand et al, 1998;
Dauphinot et al, 2001). Since EWS/FLI-1 or EWS/GAL4 can more
efficiently activate reporter constructs regulated by HTLV Ets
DNA-binding or GAL4 DNA binding elements than similar FLI-1
proteins (May et al, 1993b; Bailly et al, 1994), it has been suggested
that EWS/FLI-1 could act by overexpressing genes normally
regulated by FLI-1, resulting in tumorigenesis.
Although the EWS/FLI-1 fusion gene is capable of acting as an
oncogene, the mechanism that results in the EWS/FLI-1 transloca-
tion in ES/PNET and the direct effects of the resultant protein are
unknown. Indeed, the EWS/FLI-1 fusion protein may also have
alternate activities since mutation of the Ets DBD does not ablate
all transforming abilities and EWS/FLI-1 can also affect mRNA
splicing (Jaishankar et al, 1999; Knoop and Baker, 2001; Welford
et al, 2001). While the use of antisense oligonucleotides or
transcripts to inhibit EWS/FLI-1 expression or suppression of a
variety of signalling pathways reduced the tumorigenic potential of
ES/PNET cells (Ouchida et al, 1995; Kovar et al, 1996; Tanaka et al,
1997; Toretsky et al, 1997), these reports confirm the central role of
EWS/FLI-1 in ES/PNET, but do not address the mechanism by
which EWS/FLI-1 acts. Since cancer rarely results from a single
mutation and, like other cancers, ES/PNET cells contain other
mutations (e.g. p53), understanding the precise mechanism by
which the EWS/FLI-1 protein results in transformation will be
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simportant in the development of effective therapies for this
condition.
One approach to inhibit only the transcriptional activity of
EWS/FLI-1 is to introduce specific transcriptional suppressors
into EWS/FLI-1-transformed cells that can bind and actively
suppress EWS/FLI-1 target genes. The Kruppel associated box
(KRAB) is a protein domain of approximately 75 amino-acid
residues and has been shown to act as a potent DNA-binding-
dependent transcriptional repressor (Margolin et al, 1994; Witzgall
et al, 1994; Pengue et al, 1995; Vissing et al, 1995) that inhibits the
transcriptional machinery and/or alters the chromatin structure
(Kingston et al, 1996; Moosmann et al, 1997). Approximately, one-
third of the zinc-finger proteins of the Kruppel Cys2His2-type
contain KRAB domains at their amino termini (Bellefroid et al,
1991). Recently, constructs linking KRAB to a variety of DBD have
been shown to efficiently suppress the activity of promoter–
reporter constructs in a DNA-binding specific manner (Beerli et al,
1998; Herchenroder et al, 1999; Ma et al, 1999; de Haan et al, 2000).
Furthermore, the introduction of KRAB fused to PAX3 or Myb
DBD into rhabdomyosarcoma cells or haemopoietic tumour cell
lines, respectively, can inhibit their transformed phenotype (Rossi
et al, 1999; Ayyanathan et al, 2000; Fredericks et al, 2000; Nawrath
et al, 2000).
Thus, we have generated a construct that contains KRAB linked
to the DBD of FLI-1 and examined its ability to reverse the
phenotype of human ES/PNET cell lines or NIH3T3 cells
transformed by both human or mouse EWS/FLI-1 oncogenes.
We have demonstrated that KRAB/FLI-1 expression reduces the
ability of these cells to proliferate in low serum, form colonies in
soft agar and tumours in nude mice and reduced the upregulation
of c-myc. The initial transformation by EWS/FLI-1 and reversal by
KRAB/FLI-1 were similar for both mouse and human genes and
demonstrate that the generation of a mouse model for this disease
by manipulating the mouse genome is appropriate for elucidating
the mechanisms and validating novel therapeutic strategies.
Furthermore, these data demonstrate that inhibition of EWS/FLI-
1 transcription via sequence-specific DNA binding of the KRAB
repressor domain is sufficient to inhibit the transformed
phenotype. Therefore, targeted gene repression may be a potential
approach for the elucidation of the biological mechanisms of EWS/
FLI-1 oncogenesis and the development of novel therapeutic
strategies.
MATERIALS AND METHODS
Plasmids
The murine Ews/Fli-1 fusion gene was designed to recapitulate the
human type 1 EWS/FLI-1 fusion sequence. The murine Ews/Fli-1
fusion cDNA construct was generated by first amplifying exons
1–7 on murine Ews cDNA and exons 6–9 of murine Fli-1 cDNA,
and then fusing both partial cDNAs together by using an overlap
extension PCR technique. The murine Ews/Fli-1 and human type 1
EWS/FLI-1 fusion genes were cloned into the pEF-BOS vector
(Mizushima and Nagata, 1990) containing a puromycin resistance
gene. Similar constructs were also generated using the cytomegalo-
virus (CMV) minimal promoter. The KRAB/FLI-1 fusion gene was
made by replacing EWS cDNA (amino acids 1–244) in human
EWS/FLI-1 type I fusion cDNA with a KRAB domain derived from
KOX1 (Figure 2). Mutant KRAB (amino acids 18 and 19 were
changed from DV to AA) was used as negative control because the
two substitutions abolish binding to the corepressor KAP-1 and
thus the KRAB repressor function (Friedman et al, 1996;
Moosmann et al, 1997; Figure 2). A KOZAK consensus sequence
and initiation codon was added to KRAB and mutant KRAB
by PCR amplification using the oligonucleotide; 50-
TCCCCGCGGTTCGCCACCATGGATGCT-30. A promoterless
IRES/Neo/PolyA was cloned behind the KRAB/FLI-1 or mutant
KRAB/FLI-1 fusion genes to allow selection of clones with high
expression.
Cell culture and transfection
NIH3T3 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; GIBCO) supplemented with 10% fetal calf serum
(FCS; Life Technology), 3.7gl
 1 of sodium bicarbonate (BDH) and
10mM penicillin/streptomycin. SK-N-MC cell line was obtained
from the American Type Tissue Collection (ATCC) and was
cultured in Eagle’s minimal essential medium (EMEM; GIBCO)
supplemented with 10% FCS, 0.1mM nonessential amino acids
(GIBCO), 1.0mM sodium pyruvate (GIBCO), 1.5gl
 1 sodium
bicarbonate (BDH) and 10mM penicillin/streptomycin. All cell
lines were grown in 5% CO2. To examine growth of cell lines in low
serum, the cell lines were washed twice in phosphate buffered
saline (PBS) and placed in media supplemented with 1% FCS.
To establish cell lines that stably express murine or human
EWS/FLI-1, 10mg of each EWS/FLI-1 expression constructs was
electroporated into 1 10
6 NIH3T3 cells in 0.1ml culture medium
at 650mF and 200V in a 0.4ml cuvette with the BIO-RAD Gene
Pulser and Pulse Controller Transfection apparatus. Promoter
constructs without the fusion protein were similarly transfected as
‘mock’ or normal controls. The transfected cells were selected with
5mgml
 1 puromycin for 1 week. The puromycin-resistant colonies
were cloned, expanded, cryopreserved and evaluated for expres-
sion of protein by Western analysis. Clones of EWS/FLI-1-
transformed cells were similarly transfected with KRAB/FLI-1 or
mutant KRAB/FLI-1, selected with 400mgml
 1 G418 for 2 weeks
and treated as described above.
Antibodies and Western blot
Total cell lysates were prepared from cells at 70% confluence and
electrophoresed on an 8% denaturing sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) gel. The proteins
were electroblotted onto Hybond C extra membranes (Amersham).
The filters were blocked in 10% skim milk powder (Sunshine)
dissolved in TBST (20mM Tris, 137mM NaCl, 0.1% Tween 20, pH
7.6) for 1h at room temperature. Incubation with primary
antibodies were carried out at 41C overnight. Antibodies used
were anti-FLI-1 (Santa Cruz; detects EWS/FLI-1, KRAB/FLI-1 and
mutant KRAB/FLI-1), c-myc (Santa Cruz) and a/b tubulin
(Boeringer Mannheim). The secondary antibody conjugated to
horseradish peroxidase was detected using the ECL Western
Blotting Analysis System (Amersham) and exposed to Kodak X-AR
film.
Total RNA extraction
Total RNA from each of the cell lines was prepared by harvesting
the cells when they were at 70% confluency. Approximately,
1 10
6 cells were washed twice with PBS and total RNA extracted
using the High Pure RNA Isolation kit (Roche) as described by the
manufacturer and then quantified by absorbance at OD260 using a
PE spectrophotometer (Perkin-Elmer).
Cell proliferation assay
The growth rate of each cell line was examined in media containing
1% FCS. NIH3T3 (5 10
3 cells) or SK-N-MC (1 10
3 cells) were
seeded in triplicate in 3cm wells in low serum media and cell
proliferation measured by direct counting of trypan-blue negative
cells.
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British Journal of Cancer (2003) 88(1), 137–145 & 2003 Cancer Research UKSoft agar assays
In all, 5000 cells of each cell line were trypsinized and suspended in
2ml of complete medium plus 0.3% agarose (Promega). The agar–
cell mixtures were plated on top of a bottom layer with 1%
complete medium agar mixture in triplicate. After 2–3 weeks, the
agar assays were scored for viable colonies.
Mouse tumour formation assay
The tumorigenic potential of each cell line was evaluated by
injecting of cell suspensions into 2- to 3-week-old BALB/c nu/nu
female mice. For each clone tested, five mice received subcuta-
neous injections of 2 10
6 cells (NIH3T3 cell lines) or 5 10
6 cells
(SK-N-MC cell lines) in a volume of 0.2ml of PBS into both dorsal
midline sides. The mice were housed in microisolator cages, given
food and water ad libitum, and handled in a sterile laminar-flow
hood. Tumour sizes were measured every 3 days using Vernier
calipers along two perpendicular axes. The volume of the tumours
was calculated by using the following formula: (mean dia-
meter)
3 p/6. All animal experimentation was performed with
approval from the Monash University Ethics Committee and
conformed to UKCCCR guidelines for the Welfare of Animals in
Experimental Neoplasia (UKCCR, 1998).
RESULTS
Transformation of NIH3T3 cells by murine or human
EWS/FLI-1 fusion genes
To determine whether murine Ews/Fli-1 is capable of transforming
cells in a similar manner to that of the human EWS/FLI-1 fusion
gene, we generated stable NIH3T3 cell lines transfected with mouse
or human EWS/FLI-1. Clones were selected with puromycin and
testing for mRNA expression by RT–PCR (data not shown).
Positive clones were demonstrated to express the expected 68kDa
EWS/FLI-1 band on Western blot analysis using a polyclonal
antibody to the C-terminal of the Fli-1 protein (Figure 1A). Cells
transfected with the empty vector were used as controls, which
displayed a weak nonspecific band that has been observed with
this commercial antibody in other studies (May et al, 1997). Both
human and mouse EWS/FLI-1 transfectant clones displayed a
variety of levels of EWS/FLI-1 fusion protein expression.
One of the hallmarks of the transformed phenotype is the ability
of cells to grow in semisolid medium (Rizzino, 1987). At least three
cell lines from each genotype were tested in triplicate with data
from representative clones shown (Figure 1B). The control cell
lines grew poorly in soft agar with only 15710 small colonies
(o20 cells) per 5000 cells plated observed. In contrast, all human
EWS/FLI-1 and murine Ews/Fli-1-expressing clones grew effi-
ciently in soft agar, forming large macroscopic colonies of greater
than 200 cells, indicating anchorage-independent growth
(Figure 1B). For example, human EWS/FLI-1-transformed clone
HuEF#1 formed 403726 colonies/5000 cells and mouse Ews/Fli-1
clone mEF#14 formed 317733 colonies/5000 cells. The efficiency
of colony formation was similar for cell lines expressing mouse or
human EWS/FLI-1. Moreover, the level of expression of the fusion
protein appeared to correspond to the efficiency of colony
formation (Figure 1A and B). For example, HuEF#16 formed
623727 colonies/5000 cells, whereas HuEF#1, which expressed less
EWS/FLI-1, only formed 403727 colonies/5000 cells. These data
demonstrate that murine EWS/Fli-1 is capable of transformation
similar to human EWS/FLI-1 and may indicate that the amount of
EWS/FLI-1 oncoprotein is proportional to the proliferation rate
and potency of transformation of NIH3T3 cells.
To determine whether c-myc, which is one of the genes known to
be activated in ES/PNET tumour cells, was also altered in our
human and murine EWS/FLI-1-transformed NIH3T3 cells, we
examined the expression levels of c-myc by Western blot
(Figure 1A). Levels of c-myc were elevated in both mouse and
human EWS/FLI-1-transfected cells compared with controls,
demonstrating that human and mouse EWS/FLI-1 activate a
similar downstream signalling cascade.
Expression of the KRAB/FLI-1 repressor in EWS/FLI-1-
transformed NIH3T3 cells
Murine and human EWS/FLI-1-transformed clones were used to
test the effects of the KRAB/FLI-1 hybrid protein on the
transformed phenotype. KRAB/FLI-1 and mutant KRAB/FLI-1
vectors were generated such that they contained the equivalent
region of the FLI-1 DBD as that found in human type I EWS/FLI-1
translocations and our human and mouse EWS/FLI-1 constructs.
The mutant KRAB domain, which was used as a control, contains
two amino-acid substitutions which abolishes KRAB binding to the
corepressor KAP-1 and thus repressor function (Margolin et al,
1994; Friedman et al, 1996). Both KRAB/FLI-1 and mutant KRAB/
FLI-1 fusion genes were placed under the control of the human EF-
1a promoter (Figure 2). These genes were followed by a
promoterless IRES/neomycin cassette to ensure that all G418-
resistant clones expressed the KRAB/FLI-1 or mutant KRAB/FLI-1
fusion genes. Protein expression in G418-resistant clones was
demonstrated by Western blot with the Fli-1 polyclonal antibody
that detected both the 68kDa EWS/FLI-1 protein band and the
45kDa KRAB/FLI-1 or mutant KRAB/FLI-1 protein bands. Three
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Figure 1 Expression and tumorigenicity of murine and human EWS/
FLI-1.( A) Western blot showing EWS/FLI-1 and c-myc protein expression
in murine and human EWS/FLI-1-transformed cells. EWS/FLI-1 (68kDa)
was detected by Fli-1 (C-19) polyclonal antibody and c-myc protein by c-
myc (N-262) polyclonal antibody. b-tubulin protein was used as a loading
control. (B) Soft-agar assay on murine and human EWS/FLI-1-transformed
NIH3T3 cell lines. In all, 5000 cells of each cell line were grown for 12 days
in a medium containing 0.3% agarose and colonies 420 cells counted.
Values shown are the mean 7 s.e.m. of triplicate samples.
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transfected with KRAB/FLI-1 and data from two representative
clones, mEF#1 and HuEF#16, are shown in Figure 3A and B. Clones
K1, K22 and mK12 are KRAB/FLI-1 and mutant KRAB/FLI-1
cotransfectants, respectively, of the mouse EWS/Fli-1-transformed
clone mEF#1 (Figure 3A). These clones had similar EWS/Fli-1
protein levels to the parental mEF#1 relative to b-tubulin controls.
Clone mK12 displayed a slightly higher expression of mutant
KRAB/FLI-1 protein levels compared with K1 and K22 cotransfec-
tants. Similar expression of human EWS/FLI-1, KRAB/FLI-1 and
mutant KRAB/FLI-1 was observed in cotransfectants of the human
EWS/FLI-1-transformed clone HuEF#16 (Figure 3B). These data
indicate KRAB/FLI-1 and mutant KRAB/FLI-1 proteins are
expressed at similar levels in these clones, and thus differences
in the transformed phenotypes of these clones is likely to be a
protein function.
KRAB/FLI-1 reduces the proliferation rate of human or
murine EWS/FLI-1 transformed NIH3T3 cells in low serum
media
Under normal culture conditions with 10% FCS there was no
difference in the growth rate of clones expressing EWS/Fli-1 and/or
KRAB/FLI-1 or mutant KRAB/FLI-1 fusion genes (data not shown).
KRAB/FLI-1 also had no effect on the growth of wild-type NIH3T3
cells. However, under low serum culture conditions (1% FCS), the
EWS/FLI-1-transformed cell lines and clones coexpressing mutant
KRAB/FLI-1 grew rapidly (Figure 4A and B), whereas EWS/FLI-1-
transformed cells coexpressing KRAB/FLI-1 had significantly
slower or no growth (Figure 4A and B). The growth rate of these
KRAB/FLI-1 cotransfectants was similar to the control cell lines
that did not express either fusion construct (Figure 4A and B).
Thus, KRAB/FLI-1 was able to inhibit the growth of both human or
murine EWS/FLI-1-transformed cells.
KRAB/FLI-1 reduces the colony formation of murine and
human EWS/FLI-1-transformed NIH3T3 cells in soft agar
The ability of KRAB/FLI-1 to reverse the transformation pheno-
type of EWS/FLI-1-expressing cells was also tested using the soft
agar assay. Human or murine EWS/FLI-1-transformed NIH3T3 cell
clones were tested in triplicate in three separated experiments.
Data from two representative EWS/FLI-1 expressing clones
(one human, HuEF#16, and one murine, mEF#1) are shown in
Figure 5A and B. After 2 weeks, the parental human and mouse
EWS/FLI-1-transformed NIH3T3 cells formed B650 and B200
colonies of 420 cells, respectively (Figure 5A and B). Clones
cotransfected with mutant KRAB/FLI-1 (mEF#1mK12 and
HuEF#16mK11), showed no significant inhibition of soft-agar
growth, however, clones cotransfected with KRAB/FLI-1
(mEF#1K1 and mEF#1K7, and HuEF#16K13 and HuEF#16K19)
showed a significant reduction in the number of colonies formed
(Figure 5A and B). These data indicate that the KRAB/FLI-1
repressor impairs anchorage-dependent growth of EWS/FLI-1-
transformed cells.
KRAB/FLI-1 impairs tumour development of murine and
human EWS/FLI-1-transformed NIH3T3 cells in nude mice
For each murine or human EWS/FLI-1-transformed clone, one
KRAB/FLI-1 cotransfectant and one mutant KRAB/Fli-1 cotrans-
fectant were inoculated into BALB/c nu/nu mice. Control cells were
not observed to form any tumours (data not shown). The
HuEF#16-transformed clone formed tumours of 222753mm
3 by
30 days after inoculation, whereas the mEF#1 transformed clone
KRAB/FLI-1 and mKRAB/FLI-1 Expression Constructs 
EF-1α IRES/Neo DBD
KRAB Repression
Domain              Human FLI-1
pA
EWS DBD
Human FLI-1
Type I Human EWS/FLI-1
Fusion Gene
3’
5’ 3’
5’
CCGCGGTTCGCCACCATGGAT
KOZAK and Initiation Codon
GAT GTA             D V
GCT GCA            A A
KRAB
mutant KRAB
Figure 2 Schematic diagram of KRAB/FLI-1 and mutant KRAB/FLI-1
expression constructs. Either KRAB or mutant KRAB with an engineered
KOZAK consensus sequence with initiation codon, ATG, was used to
replace the EWS transactivation domain in the human type I EWS/FLI-1
fusion gene. The elongation factor-1a promoter was used to express
KRAB/FLI-1 or mutant KRAB/FLI-1 and an IRES/Neo-resistance gene.
EWS/FLI-1
KF or mKF
c-myc
β-tubulin
68 kDa
45 kDa
M   #16  K13  K19  mK10
M  #1  K1   K22  mK12
EWS/Fli-1
KF or mKF
c-myc
68 kDa
45 kDa
B
A
β-tubulin
Figure 3 Western blot showing the expression of EWS/FLI-1 (68 kDa),
KRAB/FLI-1 or mutant KRAB/FLI-1 (45kDa), and alteration of c-myc
protein levels in transfected NIH3T3 cells. (A) Cells transfected with empty
construct (M¼mock control) or murine EWS/Fli-1 (#1) and subclones of
#1 cotransfected with KRAB/FLI-1 (K1, K22) or mutant KRAB/FLI-1
(mK12). (B) Similar human EWS/FLI-1-transformed clones transfected with
KRAB/FLI-1 (K13, K19) or mutant KRAB/FLI-1 (mK10).
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3 at the same stage
(Figure 6A and B). The faster tumour growth rate of this clone
HuEF#16 was consistent with its more rapid growth rate observed
in vitro and higher expression of EWS/FLI-1. Clones that expressed
both mutant KRAB/FLI-1 and EWS/FLI-1 displayed a similar
tumour growth rate in nude mice to that of the parental EWS/FLI-
1-expressing cells; however, clones that expressed KRAB/FLI-1
showed significantly reduced tumour size (Figure 6A and B). For
example, mouse Ews/Fli-1-transformed cells coexpressing mutant
KRAB/FLI-1 formed tumours in nine out of 10 mice inoculated
with a mean size of 96726mm
3 by day 30; however, at the same
stage no tumours were observed in cells coexpressing KRAB/FLI-1.
Similarly, in mice inoculated with human EWS/FLI-1 clone #16
coexpressing KRAB/FLI-1, no tumours were observed at day 27;
however, tumours formed in nine out of 10 mice inoculated with
the same clone expressing mutant KRAB/FLI-1 with a mean
volume of 147732mm
3. In all 50% of the mice inoculated with
clones expressing both KRAB/FLI-1 and EWS/FLI-1 did develop
small palpable tumours (772mm
3) in the latter part of the
experiment (Figure 6A and B); however, these tumours continued
to grow very slowly (data not shown).
KRAB/FLI-1 suppresses the transformed phenotype of SK-
N-MC, a PNET cell line
Our data demonstrate that human and mouse EWS/FLI-1 trans-
forms NIH3T3 cells and this transformation could be repressed by
KRAB/FLI-1. Since the precise aetiology of ES/PNET is not defined
and, like other cancers, these tumours contain other mutations, we
were interested to determine whether KRAB/FLI-1 could also
suppress the transformed phenotype of a human PNET cell line.
Thus, we transfected KRAB/FLI-1 (or mutant KRAB/FLI-1 as a
control) into the human PNET cell line SK-N-MC. This cell line has
a type I EWS/FLI-1 translocation similar to our constructs
generated above, but also has a defined mutation in the tumour
suppressor p53 (Beerli et al, 1998). Clones were generated and
expression of both EWS/FLI-1 (68kDa) and KRAB/FLI-1 or
mutant KRAB/FLI-1 (45kDa) proteins was examined by Western
blot (Figure 7A). Unlike our NIH3T3 transfectants, the amount of
EWS/Fli-1 fusion protein was higher than that of the KRAB/FLI-1/
mutant KRAB/FLI-1 chimaeric proteins.
To assess the ability of KRAB/FLI-1 to inhibit transformation of
SK-N-MC cells in vitro, we determined their growth rates in media
with low serum. KRAB/FLI-1-expressing clones proliferated at a
slower rate compared to both mutant KRAB/FLI-1-expressing
Growth rate of murine EWS/Fli-1 transformed NIH3T3
cells in low serum medium
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Figure 4 KRAB/FLI-1 inhibits the growth rate of EWS/FLI-1-transformed
cells in low serum medium. In all, 5000 cells were grown in 1% FCS and
cells were counted in triplicate at 3-day intervals and mean7s.d. is shown.
(A) The parental murine Ews/Fli-1-transformed NIH3T3 cells (mEF#1) and
KRAB/FLI-1 (K1, K7) or mutant KRAB/FLI-1 (mKF12) cotransfected
subclones. (B) The parental human EWS/FLI-1-transformed NIH3T3 cells
(HuEF#16) and KRAB/FLI-1 (K13, K19) or mutant KRAB/FLI-1 (mK11)
cotransfected subclones. NIH3T3 cells transfected with empty vector were
used as controls. Data are representative of three separate experiments
(mean7s.d.).
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Figure 5 KRAB/FLI-1 inhibits colony formation in soft-agar assays. (A)
The parental murine Ews/Fli-1-transformed NIH3T3 cells (mEF#1) and
KRAB/FLI-1 (K1, K7) or mutant KRAB/FLI-1 (mK12) cotransfected
subclones. (B) The parental human EWS/FLI-1-transformed NIH3T3 cells
(HuEF#16) and KRAB/FLI-1 (K13, K19) or mutant KRAB/FLI-1 (mK11)
cotransfected subclones. Data are representative of three separate
experiments and values shown are the mean7s.e.m. of triplicate samples
at day 12. Samples indicated (*) were significantly different (Po0.05).
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cells coexpressing KRAB/FLI-1 and EWS/FLI, KRAB/FLI-1-expres-
sing SK-N-MC cells continued to proliferate suggesting that the
KRAB/FLI-1 repressor could not completely abolish the trans-
formed phenotype of SK-N-MC cells, perhaps because of the
relative levels of KRAB/FLI-1 and EWS/FLI-1 proteins.
To determine the ability of the KRAB/FLI-1 repressor to
influence tumour development of SK-N-MC cells, we inoculated
clones of SK-N-MC cells expressing KRAB/FLI-1 or mutant KRAB/
FLI-1 and control cells into nude mice as described above. The
mean tumour volume was significantly reduced in KRAB/FLI-1
expressing SK-N-MC cells compared with both mock-transfected
and mutant KRAB/FLI-1-expressing cells (Figure 7C). For
example, at day 15 100% of mice had developed tumours in the
parental and mutant KRAB/FLI-1-expressing cells (mean tumour
volume 113723 and 111722mm
3, respectively), whereas only
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Figure 6 KRAB/FLI-1 inhibits the growth of tumours in nude mice. Cells
(1 10
6) were inoculated into the flanks of BALB/c nu/nu mice and
tumours measured with calipers at 3-day intervals. (A) The parental murine
Ews/Fli-1-transformed NIH3T3 cells (mEF#1) and KRAB/FLI-1 (K1) or
mutant KRAB/FLI-1 (mK12) cotransfected subclones. (B) The parental
human EWS/FLI-1-transformed NIH3T3 cells (HuEF#16) and KRAB/FLI-1
(K13) or mutant KRAB/FLI-1 (mK10) cotransfected subclones. Mean
tumour volumes (7s.e.m.) are shown and were calculated by the formula
(mean diameter)
3 p/6. The table shows the number of inoculation sites
forming tumours at each time point.
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Figure 7 KRAB/FLI-1 inhibits transformed phenotype of a human PNET
cell line (A) Western blot showing the expression of EWS/FLI-1, KRAB/FLI-
1 or mutant KRAB/FLI-1 and c-myc protein levels. (B) Growth rate in low
serum media. Cells (1 10
3) were seeded in triplicate in media
supplemented with 1% FCS and counted at 3-day intervals. Data are
shown as mean7s.d. K12, K15 and K16 were KRAB/FLI-1-expressing
clones while mK3 and mK15 were mutant KRAB/FLI-1 expressing clones.
Mock indicates the empty vector transfected control. (C) The tumour
growth rate in BALB/c nu/nu mice. Cells (1 10
5) were inoculated into the
flanks of BALB/c nu/nu mice and palpable tumours were measured with
calipers at 3-day intervals. Mean tumour volumes (+s.e.m.) are shown and
were calculated by the formula (mean diameter)
3 p/6. The table shows
the number of inoculation sites forming tumours at each time point.
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British Journal of Cancer (2003) 88(1), 137–145 & 2003 Cancer Research UK50% of mice inoculated with KRAB/FLI-1-expressing cells had
palpable tumours (mean volume 3478mm
3). These data indicate
that the KRAB/FLI-1 repressor could significantly reduce tumour
development, similar to the in vitro data.
DISCUSSION
The majority of Ewing’s sarcoma and primitive neuroectodermal
tumours are associated with a t(11;22)(q24;q12) chromosomal
translocation, which results in the production of an EWS/FLI-1
fusion protein that comprises the amino terminus of the EWS gene
and the carboxyl terminus of the FLI-1 gene. The continued
expression of human EWS/FLI-1 protein has been shown to be
sufficient and necessary for in vitro transformation of cell lines
(May et al, 1993a,b). Although EWS/FLI-1 has been shown to be a
potent transcription factor (Delattre et al, 1992; May et al, 1993a,b;
Bailly et al, 1994 and references therein), whether its ability to
transform is due only to its transcriptional activation activity has
been unclear. Furthermore, its importance in the aetiology of
human disease is also unclear as these human tumours are likely to
contain multiple mutations. To address these issues, we have
demonstrated herein that both human and murine EWS/FLI-1 can
transform NIH3T3 cells and that the transformation phenotype in
these cells and a human ES/PNET cell line can be inhibited by a
specific transcriptional repressor KRAB/FLI-1. The latter also
sheds light on the mechanism of EWS/FLI-1 transformation since
the FLI-1 DBD is necessary to target an active repressor domain to
the effector site.
In order to facilitate mouse model studies, we engineered a
murine Ews/Fli-1 fusion gene to mimic the human fusion gene
formed by the most common chromosomal translocation,
t(11;22)(q24;q12), observed in ES/PNET. This murine fusion gene
showed 98% nucleotide identity to the human fusion gene and
fibroblast transfectants showed similar transformed phenotypes to
human EWS/FLI-1-transfected cells. This included anchorage-
independent growth in soft agar, increased proliferation rate in low
serum media and tumour development in BALB/c nu/nu mice.
Variations in the efficiency of clones to display a transformed
phenotype appeared to correlate with the level of the EWS/FLI-1
fusion proteins rather than the species from which the sequences
were derived. These findings validate at a protein level previous
reports that suggested a correlation between the mRNA levels of
human EWS/FLI-1 and the proliferation rate of ES/PNET cells
(Tanaka et al, 1997). These data indicate the feasibility and validity
of a murine model for ES/PNET, which would provide a valuable
resource for elucidating the mechanisms of EWS/FLI-1 transfor-
mation and the development of a model in which to test novel
therapeutic strategies.
To inhibit EWS/FLI-1 transactivation activity in both human
and mouse EWS/FLI-1-transformed cells and a human PNET cell
line, we generated a KRAB/FLI-1 chimaeric protein. When bound
to DNA by a specific DBD, the KRAB domain binds to the
corepressor KAP-1, which suppresses transcription by either
directly inhibiting the transcriptional machinery and/or by altering
the chromatin structure (Friedman et al, 1996; Le Douarin et al,
1996; Moosmann et al, 1996; Darnell and Richardson, 1999).
Indeed, KRAB/FLI-1 inhibited EWS/FLI-1 transformation in our
study. Since KRAB/FLI-1 will only inhibit transcription of genes
with FLI-1 DNA-binding elements and will not have any effect
on the nontransactivation activity of EWS/FLI-1, these data
demonstrate that transactivation of FLI-1 target genes by EWS/
FLI-1 is essential for its ability to transform. This is in contrast
with previous data, which indicated that mutation of the EWS/FLI-
1 DBD did not eliminate its ability to transform (Jaishankar et al,
1999; Welford et al, 2001). We suggest that the remaining
transformation activity reported for the mutant EWS/FLI-1 could
be explained by the ability of the fusion protein to still complex
with the transcription initiation complex independent of DNA-
binding and/or residual-DNA-binding activity not detected in in
vitro assays.
Our observation that suppression of EWS/FLI-1-activated genes
inhibits transformation in vitro and in vivo is consistent with
previous studies, which demonstrated that expression of a FLI-1
DBD can suppress Ewing’s sarcoma and EWS/FLI-1-transformed
cell growth in vitro (Kovar et al, 1996; Welford et al, 2001),
presumably by competing with EWS/FLI-1 DNA binding. How-
ever, in Welford et al (2001) expression of this FLI-1 DBD did not
affect tumour growth of EWS/FLI-1-transformed NIH3T3 cells in
vivo. This was suggested to be a result of DBD-independent effects
of the EWS/FLI-1 protein, although inhibition of an ES cell line was
observed (Welford et al, 2001). It is possible that the levels of the
human FLI-1 DBD protein used were not sufficient to inhibit EWS/
FLI-1 transactivation in murine NIH3T3 cells in vivo. This is
supported by our study where the active repressor KRAB/FLI-1
efficiently inhibited transformed cell growth in vitro and in vivo,
whereas similar levels of mutant KRAB/FLI-1 had no significant
effect on the transformed phenotype. It is logical to conclude that
levels of an active repressor required to inhibit transcription would
be much lower than those of a DNA-binding competitor.
The inhibition of EWS/FLI-1 is the first demonstration of the
KRAB domain suppressing the action of an ETS factor. Many
members of this large family of transcription factors have also
been implicated as potential oncogenes in other malignancies
including acute lymphoblastic leukaemia, myelomonocytic leu-
kaemias and breast cancer (Santoro et al, 1992; Ichikawa et al,
1994; Golub et al, 1995; Chen et al, 1996; Tymms et al, 1997). Thus,
similar use of DNA sequence-specific transcriptional repressors
will be an important avenue for the development of broader
therapeutic strategies.
The use of a targeted and potent repressor domain increases the
efficiency of transcriptional repression of cancer-causing genes.
Thus, an active transcriptional repressor is more efficient for the
inhibition of tumour growth than overexpression of a DBD.
Effective therapies will thus be possible with much lower amounts
of protein.
A major issue in understanding the aetiology of ES/PNET
is understanding how EWS/FLI-1 activates the many genes
shown to be increased. Since the promoters of some of the genes
activated in ES/PNET are believed to not bind FLI-1, including
c-myc, it has been suggested that the EWS/FLI-1 protein may
have additional properties such as RNA processing (Jaishankar
et al, 1999) or the binding and modulation of genes not
normally regulated by FLI-1 (May et al, 1993a). Significantly,
c-myc was increased in each of our cell lines expressing human or
mouse EWS/FLI-1 and decreased in clones coexpressing KRAB/
FLI-1. Since the KRAB domain shows no DNA-binding activity
(Margolin et al, 1994) the regulation of this gene together with
transformed phenotype appears to be a result of FLI-1-specific
DNA binding. This suggests that the many genes that are activated
by EWS/FLI-1, but not by direct FLI-1 DNA binding, may be
indirectly activated. The mechanism by which indirect activation
occurs is unclear; however, the analysis of KRAB/FLI-1 expressing
ES/PNET cell lines will enable the identification of genes
specifically regulated through FLI-1-specific DNA binding in ES/
PNET. The identification of the primary target genes of EWS/FLI-1
will be important in understanding the oncogenic processes in ES/
PNET and will further assist in the development of new therapeutic
strategies.
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